NCT00971295已完成1 期
Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers
Bial - Portela C S.A.1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2007年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Cmax - Maximum Observed Plasma Concentration
研究概览
简要总结
The primary objective was to investigate whether multiple-dose administration of eslicarbazepine acetate affects the pharmacokinetics of metformin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female subjects aged between 18 and 45 years, inclusive.
- •Body mass index (BMI) between 19 and 30 kg/m2, inclusive.
- •Healthy as determined by pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead ECG.
- •Negative tests for HBsAg, anti-HCVAb and HIV-1 and HIV-2 Ab at screening
- •Clinical laboratory test results clinically acceptable at screening and admission to each treatment period.
- •Negative screen for alcohol and drugs of abuse at screening and admission to each treatment period.
- •Non-smokers or who smoke ≤ 10 cigarettes or equivalent per day.
- •Able and willing to give written informed consent.
- •(If female) Not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: double barrier or intrauterine device.
- •(If female) Negative urine pregnancy test at screening and admission to each treatment period.
排除标准
- •Clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders.
- •Clinically relevant surgical history.
- •History of relevant atopy or drug hypersensitivity.
- •History of alcoholism or drug abuse.
- •Consumed more than 14 units of alcohol a week.
- •Significant infection or known inflammatory process at screening or admission to each treatment period.
- •Acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period.
- •Used medicines within 2 weeks of admission to first period that may affect the safety or other study assessments, in the investigator's opinion.
- •Used any investigational drug or participated in any clinical trial within 6 months prior to screening.
- •Participated in more than 2 clinical trials within the 12 months prior to screening.
- •Donated or received any blood or blood products within the 3 months prior to screening.
- •Vegetarians, vegans or with medical dietary restrictions.
- •Could not communicate reliably with the investigator.
- •Unlikely to co-operate with the requirements of the study.
- •Unwilling or unable to give written informed consent.
- •(If female) Pregnant or breast-feeding.
- •(If female) Of childbearing potential and she did not use an approved effective contraceptive method (double-barrier or intra-uterine device) or she used oral contraceptives.
研究组 & 干预措施
Treatment Sequence A
Experimental
Eslicarbazepine acetate + Metformin period followed by washout period followed by Metformin period
干预措施: Metformin (Drug)
Treatment Sequence A
Experimental
Eslicarbazepine acetate + Metformin period followed by washout period followed by Metformin period
干预措施: Eslicarbazepine acetate (Drug)
Treatment Sequence B
Experimental
Metformin period followed by washout period followed by Eslicarbazepine acetate + Metformin period
干预措施: Metformin (Drug)
Treatment Sequence B
Experimental
Metformin period followed by washout period followed by Eslicarbazepine acetate + Metformin period
干预措施: Eslicarbazepine acetate (Drug)
结局指标
主要结局
Cmax - Maximum Observed Plasma Concentration
时间窗: 3 weeks
Maximum Observed Plasma Metformin Concentration
次要结局
- Tmax - Time of Occurrence of Cmax(3 weeks)
- AUC0-∞ - Area Under the Plasma Concentration From Time Zero to Infinity(3 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy VolunteersEpilepsyNCT02777671Bial - Portela C S.A.20
已完成
1 期
Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral ContraceptivePartial EpilepsyNCT00898560Bial - Portela C S.A.20
终止
2 期
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I DisorderBIPOLAR I DISORDERNCT01824602Bial - Portela C S.A.38
已完成
1 期
Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy SubjectsEpilepsyNCT00987558Bial - Portela C S.A.30
已完成
3 期
Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in ChildrenPartial Epilepsy in Children and AdolescentsNCT00988156Bial - Portela C S.A.304